<?xml version="1.0" encoding="UTF-8"?>
<p>Other EORTC QLQ‐C30 and QLQ‐MY24 subscales show largely similar trends and trajectories by allocated treatment. In the intensive pathway CVAD patients had worse Diarrhoea, Insomnia and Side Effects compared to CTD patients at 3 months. It appeared that patients in the CTD group had worse Constipation than patients on CVAD at 3 months (Figure 
 <xref rid="bjh15459-sup-0001" ref-type="supplementary-material">S1</xref>A). In the non‐intensive pathway, patients on CTDa had worse Constipation than patients on MP at 3 months (Figure 
 <xref rid="bjh15459-sup-0001" ref-type="supplementary-material">S1</xref>B). In the maintenance phase, Constipation was worse in those on thalidomide maintenance therapy compared to observation only both at 3 and 6 months (Figure 
 <xref rid="bjh15459-sup-0001" ref-type="supplementary-material">S1</xref>C).
</p>
